KVCGTan
2021-07-27
Interesting. Like?
After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情之后，BioNTech 将目光投向了疟疾</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":809683583,"tweetId":"809683583","gmtCreate":1627365544142,"gmtModify":1631892961244,"author":{"id":3570938362108330,"idStr":"3570938362108330","authorId":3570938362108330,"authorIdStr":"3570938362108330","name":"KVCGTan","avatar":"https://static.tigerbbs.com/2126be6bc046089345232547cb51d38a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Interesting. Like?</p></body></html>","htmlText":"<html><head></head><body><p>Interesting. Like?</p></body></html>","text":"Interesting. Like?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/809683583","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","kind":"news","pubTimestamp":1627356038,"share":"https://www.laohunote.com/m/news/1153403036?lang=zh_CN&edition=full","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情之后，BioNTech 将目光投向了疟疾</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p><p><blockquote>BioNTech 进入 2020 年，成为一家备受尊敬（尽管有点不为人知）的生物技术公司。一年多后，该公司因研制出最成功的冠状病毒疫苗之一而闻名于世，其股价上涨了 150%，联合创始人乌古尔·沙欣 (Uğur Şahin) 现已成为全球 500 位最富有的人之一。不太寒酸。</blockquote></p><p> On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p><p><blockquote>周一，该公司宣布了其下一个任务：独自开发一种疫苗，可以预防疟疾，疟疾是世界上最致命的疾病之一，也是疫苗生产商臭名昭著的谜团。</blockquote></p><p> The Hardest Pathogen to Hack</p><p><blockquote>最难破解的病原体</blockquote></p><p> There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p><p><blockquote>目前只有一种被批准的疟疾疫苗。葛兰素史克开发的Mosquirix在四年内只有39%的有效率。与此同时，2019年有2.29亿例疟疾病例，其中94%发生在非洲，每年有40万人死于这种疾病，几乎都是非洲儿童。</blockquote></p><p> BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p><p><blockquote>BioNTech 将使用信使核糖核酸 (mRNA) 开发疟疾疫苗候选物，该信使核糖核酸 (mRNA) 指导人体制造病毒部分以引发免疫反应。该公司还将在非洲的工厂生产和测试其他候选产品：</blockquote></p><p> <ul> <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li> <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li> </ul> \"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p><p><blockquote><ul><li>牛津大学今年推出了一种这样的候选药物，这是超越世界卫生组织75%疗效目标的第一枪。在一项对布基纳法索450名儿童的研究中，它预防了77%的病例，一项对4800名儿童进行的确认结果的试验正处于规划阶段。</li><li>BioNTech的目标是让mRNA疟疾和结核病疫苗在明年准备好进行临床试验，但表示疟疾可能与癌症一样难以研究。该公司为早期开发设定了2000万至5000万欧元的基准。</li></ul>“这不会是本垒打，”沙欣告诉<i>金融时报</i>“这是一种非常非常难以破解的病原体。”BioNTech开发的任何疟疾疫苗都将在非营利的基础上在非洲销售，该公司的目标是在一到两年内疫苗的有效性达到90%。</blockquote></p><p> <b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p><p><blockquote><b>侵入性和回避性：</b>疟疾是由一种复杂的寄生虫引起的，这种寄生虫可能会产生数千种抗原，并且有许多逃避免疫系统的方法。与许多疾病不同，由于其复杂性，有可能反复感染。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情之后，BioNTech 将目光投向了疟疾</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria<blockquote>新冠疫情之后，BioNTech 将目光投向了疟疾</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-07-27 11:20</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p><p><blockquote>BioNTech 进入 2020 年，成为一家备受尊敬（尽管有点不为人知）的生物技术公司。一年多后，该公司因研制出最成功的冠状病毒疫苗之一而闻名于世，其股价上涨了 150%，联合创始人乌古尔·沙欣 (Uğur Şahin) 现已成为全球 500 位最富有的人之一。不太寒酸。</blockquote></p><p> On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p><p><blockquote>周一，该公司宣布了其下一个任务：独自开发一种疫苗，可以预防疟疾，疟疾是世界上最致命的疾病之一，也是疫苗生产商臭名昭著的谜团。</blockquote></p><p> The Hardest Pathogen to Hack</p><p><blockquote>最难破解的病原体</blockquote></p><p> There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p><p><blockquote>目前只有一种被批准的疟疾疫苗。葛兰素史克开发的Mosquirix在四年内只有39%的有效率。与此同时，2019年有2.29亿例疟疾病例，其中94%发生在非洲，每年有40万人死于这种疾病，几乎都是非洲儿童。</blockquote></p><p> BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p><p><blockquote>BioNTech 将使用信使核糖核酸 (mRNA) 开发疟疾疫苗候选物，该信使核糖核酸 (mRNA) 指导人体制造病毒部分以引发免疫反应。该公司还将在非洲的工厂生产和测试其他候选产品：</blockquote></p><p> <ul> <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li> <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li> </ul> \"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p><p><blockquote><ul><li>牛津大学今年推出了一种这样的候选药物，这是超越世界卫生组织75%疗效目标的第一枪。在一项对布基纳法索450名儿童的研究中，它预防了77%的病例，一项对4800名儿童进行的确认结果的试验正处于规划阶段。</li><li>BioNTech的目标是让mRNA疟疾和结核病疫苗在明年准备好进行临床试验，但表示疟疾可能与癌症一样难以研究。该公司为早期开发设定了2000万至5000万欧元的基准。</li></ul>“这不会是本垒打，”沙欣告诉<i>金融时报</i>“这是一种非常非常难以破解的病原体。”BioNTech开发的任何疟疾疫苗都将在非营利的基础上在非洲销售，该公司的目标是在一到两年内疫苗的有效性达到90%。</blockquote></p><p> <b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p><p><blockquote><b>侵入性和回避性：</b>疟疾是由一种复杂的寄生虫引起的，这种寄生虫可能会产生数千种抗原，并且有许多逃避免疫系统的方法。与许多疾病不同，由于其复杂性，有可能反复感染。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":846,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/809683583"}
精彩评论